Genzyme Corporation is a biotechnology company that develops and markets innovative products and services for unmet medical needs.

About MPS I

MPS I is a rare, progressive, debilitating disease caused by a deficiency of the enzyme alpha L-iduronidase that affects an estimated 3,000 to 4,000 people worldwide, including approximately 1,000 in the United States. Patients who lack this enzyme experience a wide range of problems related to the disease, including progressive damage to the heart, lungs, liver, and kidneys and in some cases decreased mental function. The early signs of MPS I include enlarged head size, a combination of recurrent ear, nasal, and respiratory infections, and hernias, which often plague healthy infants. Additional symptoms may include corneal clouding, coarse facial features, hearing loss, or joint deformities.

Genzyme Announces FDA Approval for Aldurazyme

In April 2003, the U.S. Food and Drug Administration (FDA) approved Aldurazyme, the first treatment for individuals with MPS I. Aldurazyme is approved in the 15 European Union countries, Iceland and Norway. Aldurazyme (laronidase) is indicated for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms. The risks and benefits of treating mildly affected patients with the Scheie form have not been established. Aldurazyme has been shown to improve pulmonary function and walking capacity. Aldurazyme is available by prescription only. To learn more, please visit for full information.

Genzyme Offers Help with Insurance Questions for MPS I

If you live in the U.S. and are starting treatment with Aldurazyme, you may have many questions about your health insurance coverage. It is important to understand your health insurance policy, and Genzyme has a dedicated group of health care professionals who can provide free and confidential help.

Genzyme Treatment Support is a team of experienced nurses, social workers, and other health care professionals with expertise in U.S. public and private health insurance, as well as the U.S. health care delivery system. These professionals can help provide patients in the U.S. with the support necessary for your care, including:

Help in understanding the benefits available through your current insurance plan.
Assistance in finding alternative insurance options.
Help in coordinating your care by working closely with your physician and your insurance company, as needed.

Genzyme Treatment Support can support you through the process and assist you with your needs. Call 800-745-4447 for more information.